Olmy-H 40 Tablet is a combination antihypertensive medication containing Hydrochlorothiazide 12.5 mg and Olmesartan Medoxomil 40 mg. Hydrochlorothiazide is a thiazide diuretic that promotes the excretion of sodium and water by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, thereby reducing blood volume and lowering blood pressure. Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, preventing vasoconstriction and aldosterone secretion, which leads to vasodilation and decreased peripheral resistance. The combination of these two agents provides a complementary mechanism to effectively manage hypertension, improving blood pressure control in patients who may not respond adequately to monotherapy. Olmy-H 40 is indicated for the treatment of essential hypertension to reduce the risk of cardiovascular events such as stroke and myocardial infarction. It is important to monitor renal function, electrolytes, and blood pressure regularly during therapy. Caution is advised in patients with impaired renal or hepatic function, electrolyte imbalances, or hypersensitivity to sulfonamides. This medication should be used under medical supervision with adherence to prescribed dosage and lifestyle modifications for optimal therapeutic outcomes.